Noemi Reguart· @NReguart · X·· 1 天前评分70
正文 · 原文
🚨 Awaited SAFFRON #ESMO26 OSI + savolitinib vs ChT EGFRm/MET+ NSCLC after 1L OSI. First positive targeted strategy post-progression!👏👏
🔹 PFS: 7.6 vs 5.4 mo (HR 0.55)
🔹 OS: 17.8 vs 12.9 mo (HR 0.68)
@NEJM New roads, challenges: biomarker testing IHC/NGS Tx, Liquid in focus!
70 浏览 · 3 赞 · 2 转发 · 0 回复
来源：Noemi Reguart · x.com